New approach to heart failure in diabetes mellitus

Abstract

Despite the introduction of complex pharmacological approaches, heart failure (HF) is still a therapeutic challenge, especially when it is associated with type 2 diabetes mellitus (T2DM). Recently, large clinical trials have shown multiple benefits from using sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 agonists not only in the field of diabetes but also as agents reducing the risk of cardiovascular events and the frequency of hospitalisation due to HF deterioration. This has been reflected in the recent American Heart Association (ACC) 2018 guidelines for risk reduction in patients with T2DM and cardiovascular diseases, and in the ACC/American Heart Association (AHA) 2019 guidelines for primary prevention of cardiovascular diseases.